FDA Grants Breakthrough Status to Lenvatinib/Pembrolizumab for Endometrial Cancer

August 1, 2018 – The FDA has granted a breakthrough therapy designation to the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy. The designation, which will expedite the development and review of the combination in this setting was based on interim data … (leggi tutto)